Effect of "Non-Oncology" Drugs on Tumor Growth and Patient Survival
- Continuing Education
This course will discuss specific examples of “non-oncology” drugs prescribed for co-morbidities such as hypertension or anxiety, which may have unexpected effects on tumor growth, either directly or due e.g. to effects on the tumor microenvironment, immune response.
On This Page
Overview
This is a one-day in person course designed to both inform clinical practice and to catalyze an important direction of research
This one-day meeting is focused on potential effects of drugs oncologists and internists administer for “non-oncology” purposes, i.e. to treat patients’ co-morbidities such as hypertension, diabetes, and cerebral edema etc.
“Non-oncology” drugs given to oncology patients may have
- Direct effects on the tumor
- Effects on the microenvironment and/or
- Effects on the immune system
Drawing attention to the possibility of “unintended targets” of the “non-oncology drugs” has the potential to enable us to
- Decrease morbidity and/or mortality in subsets of patients
- identify potential new targets and research directions using available pathway and clinical data
- Protect the health of many patients who are being treated by specific drugs they should not be given
Please send your abstract to Dr. Lynn Caporale caporale@usa.net
Learning Objectives
- Reassess the choice of "non-oncology" drugs used to treat co-morbidities in their patients who have also been diagnosed with cancer
- Discuss specific examples of “non-oncology” drugs prescribed for co-morbidities such as hypertension or anxiety, may have unexpected effects on tumor growth, either directly or due e.g. to effects on the tumor.
- Understand drugs with short-term benefits for cancer patients (e.g. dexamethasone used vs glioblastoma brain swelling) can have long-term negative effects, cautioning physicians, & encouraging medical researchers to identify alternative treatments.
- Assess available treatments for patient comorbidities for their potential effects on tumor growth.
Developed and Offered By:
Continuing Education courses are developed by faculty from Harvard Medical School's teaching hospitals and accredited by Harvard Medical School. This course is offered by Mass General Hospital.
Participant Types
Internists, Immunologists,Pharmacists, Physician Assistants, Nurse Practitioners, Primary Care Physicians, Medical Students, Oncologists, Neuro Oncologists, and PhD Researchers.
Faculty
Rakesh K. Jain, PhD
Course Director
- A. Werk Cook Professor of Radiation Oncology, Radiation Oncology, Harvard Medical School
- Director, Steele Laboratory, Massachusetts General Hospital
Eric Wong, MD
Course Director
- Director, Medical Neuro-Oncology, Brown University Health Cancer Institute
Lynn Caporale, PhD
Course Director
- Translational Medicine Consultant
Michael Feigin, PhD
Associate Professor, Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center
Emily Gallagher, MD, PhD
Associate Professor of Medicine, Endocrinology, Diabetes and Bone Disease
Akshitkumar Mistry, MD
Assistant Professor of Neurosurgery University of Louisville School of Medicine
Chris Sander, PhD
Director, cBio Center at Dana-Farber Cancer Institute
Special Advisor for Quantitative Biology at the Ludwig Center at Harvard
Associate Member, Broad Institute at Harvard and MIT
Hasan Slika, MD
Postdoctoral Fellow, Department of Neurosurgery, Johns Hopkins
Vikas Sukhatme, MD, DsC
Robert W. Woodruff Professor of Medicine Emory School of Medicine Founding Director, Morningside Center for Innovative and Affordable Medicine
Course Fees
Fee Disclaimer
You may register through our secure online environment and will receive an email confirmation upon receipt of your payment.
At the end of the registration process, a $10 non-refundable processing fee will be added to your registration.
Early Registration Deadline:
| Role | Standard Price | Early Registration Price |
|---|---|---|
| Physician (MD/DO) | $350.00 | $315.00 |
| Nurse (RN/APRN) | $200.00 | $180.00 |
| PA | $200.00 | $180.00 |
| Resident/Fellow | $250.00 | $225.00 |
| Allied Health Professional / Other | $300.00 | $270.00 |
For the medical and graduate student discount code please contact Dr. Lynn Caporale at caporale@usa.net
Accreditation
The Harvard Medical School designates this live activity for a maximum of 6.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.50 MOC in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.
The American Medical Association (AMA) has an agreement of mutual recognition of continuing medical education (CME) credit with the European Union of Medical Specialties (UEMS). Additional information regarding this agreement may be found on the European Union of Medical Specialties website.
The Royal College of Physicians and Surgeons of Canada recognizes conferences and workshops held outside of Canada that are developed by a university, academy, hospital, specialty society or college as accredited group learning activities.